Key clinical point: The number needed to vaccinate to prevent one case of influenza among patients taking adalimumab is much lower than for healthy patients.
Major finding: The number needed to vaccinate (NNV) to prevent one case of influenza among healthy control patients was 71, compared with an NNV of 10 for patients taking the TNF inhibitor adalimumab (Humira).
Study details: An observational cohort of study that compared 15,132 adult patients exposed to adalimumab and 71,221 healthy controls.
Disclosures: Dr. Adami had no financial conflicts to disclose. Several coauthors disclosed relationships with companies including Abiogen Pharma, Grünenthal, Amgen, Janssen-Cilag, Mundipharma, and Pfizer.
Adami G et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):192-3. Abstract OP0230, doi: 10.1136/annrheumdis-2019-eular.3088.